Aviptadil

Drug Profile

Aviptadil

Alternative Names: DasKloster 1000; DasKloster 1000-01; DasKloster 1000-02; DasKloster 1000-03; DasKloster 1000-04; DK 1000; Vasoactive intestinal peptide

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator mondoBIOTECH
  • Developer Lung Rx; mondoBIOTECH; RELIEF THERAPEUTICS Holding
  • Class Gastrointestinal hormones; Neuropeptides; Peptide hormones
  • Mechanism of Action Vasoactive intestinal peptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Adult respiratory distress syndrome; Pulmonary sarcoidosis; Acute lung injury; Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute lung injury; Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Pulmonary hypertension; Pulmonary sarcoidosis

Highest Development Phases

  • Phase III Pulmonary sarcoidosis
  • Phase II Adult respiratory distress syndrome
  • Discontinued Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension

Most Recent Events

  • 18 Jul 2016 Phase-II clinical trials in Adult respiratory distress syndrome in Switzerland (Parenteral)
  • 18 Jul 2016 Phase-III for Pulmonary sarcoidosis in European Union (Inhalation)
  • 21 Apr 2016 THERAMetrics enter into a binding agreement to combine with Relief Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top